ARS Pharmaceuticals, Inc. — Director's Dealing 2025

Mar 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-03-05

Reporting Person: Shawver Laura (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-05	Common Stock	M	400	$4.85	Acquired	210746	Direct
2025-03-05	Common Stock	S	400	$11	Disposed	210346	Direct
2025-03-06	Common Stock	M	49600	$4.85	Acquired	259946	Direct
2025-03-06	Common Stock	S	49600	$11.2106	Disposed	210346	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-05	Stock Option (Right to Buy)	$4.85	M	400	Disposed	2032-01-31	Common Stock (400)	Direct
2025-03-06	Stock Option (Right to Buy)	$4.85	M	49600	Disposed	2032-01-31	Common Stock (49600)	Direct

Footnotes

F1: The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.

F2: The weighted average sale price for the transaction reported was $11.2106 and the range of prices were between $11.00 and $11.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F3: Immediately exercisable.